Maria de la Rosa
The University of Texas MD Anderson Cancer Center, Houston, TXAuthored Items
Maria Badillo, MSN, RN, Diana Nava, RN, Maria de la Rosa, Wendy Chen, PA, Maria Guerrero, DNP, MS, RN, Michael Wang, MD
November 2019 Vol 10, No 11
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.
Last modified: November 6, 2019